4 research outputs found
Incontinentia pigmenti revisited. A novel nonsense mutation of the IKBKG gene
Aim:
To describe and evaluate the clinical and molecular findings of patients
with incontinentia pigmenti (IP) in Greece.
Methods:
We examined 12 female patients, initially aged 2 weeks to 7 months with
clinical diagnosis of IP. Standard tests were performed including skin
biopsies and ocular, dental and neurologic examinations. Molecular
analysis was carried out on 8 out of 12 cases.
Results:
The initial clinical examination was stage 1 (vesicular lesions), stage
2 (verrucous lesions) or stage 3 (hyperpigmented linear lesions of the
trunk/limbs). At the final clinical examination, 10 of our patients had
typical vesicular, verrucous or mixed hyper-hypopigmented skin lesions
which had persisted from the neonatal period; seven had delayed
dentition or conical teeth; two had developmental delay; one had
microcephaly and strabismus and two had scarring alopecia. In seven
patients, deletion of exons 4-10 of the IKBKG gene was found. In one
patient, skewed X-inactivation was demonstrated and a novel mutation
p.Gln332X was found. The mothers’ DNA analyses were all normal.
Conclusion:
In our sample, all the cases were sporadic and the diagnosis of IP was
based mainly on clinical features and confirmed with skin histology.
Molecular analysis was used to find the mutations, in some cases to
confirm diagnosis and to identify the carriers, which are crucial for
prenatal and preimplantation diagnosis
Six-Year Retrospective Review of Hospital Data on Antimicrobial Resistance Profile of Staphylococcus aureus Isolated from Skin Infections from a Single Institution in Greece
Objective: To determine the prevalence of resistant strains of Staphylococcus aureus (S. aureus) isolated from Skin and soft tissue infections (SSTI) to various antibiotics. Material and Methods: All culture-positive results for S. aureus from swabs taken from patients presenting at one Greek hospital with a skin infection between the years 2010–2015 were examined retrospectively. Bacterial cultures, identification of S. aureus and antimicrobial susceptibility testing were performed using the disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines and European Committee on Antimicrobial testing (EUCAST) breakpoints. EUCAST breakpoints were applied if no CLSI were available. Results: Of 2069 S. aureus isolates identified, 1845 (88%) were resistant to one or more antibiotics. The highest resistance was observed for benzylpenicillin (71.9%), followed by erythromycin (34.3%). Resistant strains to cefoxitin defined as MRSA (methicillin-resistant S. aureus) represented 21% of total isolates. Interestingly, resistance to fusidic acid was 22.9% and to mupirocin as high as 12.7%. Low rates were observed for minocycline, rifampicin and trimethoprim/sulfamethoxazole (SXT). Resistance to antibiotics remained relatively stable throughout the six-year period, with the exception of cefoxitin, fusidic acid and SXT. A high percentage of MRSA strains were resistant to erythromycin (60%), fusidic acid (46%), clindamycin (38%) and tetracycline (35.5%). Conclusions: Special attention is required in prescribing appropriate antibiotic therapeutic regimens, particularly for MRSA. These data on the susceptibility of S. aureus may be useful for guiding antibiotic treatment
DNA barcoding in native plants of the Labiatae (Lamiaceae) family from Chios Island (Greece) and the adjacent Çeşme‐Karaburun Peninsula (Turkey)
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas
The expression of the cyclin-dependent kinase inhibitor (CDKI) p27 protein was investigated in relation to (1) the expression of the cell cycle regulators p53, Rb and p16 and (2) the proliferation profile as determined by the expression of Ki67, cyclin A, and cyclin BI in 80 cases of de novo diffuse large B-cell lymphomas (DLBCL). P27 expression was low/null in large tumor cells in 58/80 cases and intermediate/high in 22/80 cases. Increased expression of p53 protein was observed in 39/80 cases. Decreased expression of Rb and p16 proteins was mutually exclusive and was observed in 5/80 and 14/80 cases, respectively. The analysis of the p27 expression status (low/null versus intermediate/high) with respect to the p53 and/or Rb/p16 expression status showed that low/null p27 expression was significantly correlated with increased p53 expression (P = .018) and showed a strong trend for correlation with concurrent increased p53 expression and decreased Rb or p16 expression (P = .050). These findings suggest a tendency for concurrent alterations of the cell cycle regulators p27, p53, and Rb or p16 in DLBCL, which might result in impaired tumor growth control. Indeed, the analysis of the combined p27/p53/Rb/p16 expression status with respect to the proliferation profile showed that (1) three alterations in the combined p27/p53/Rb/p16 status (i.e., low/null P27 expression, increased expression of p53, and decreased expression of Rb or p16) were significantly correlated with increased expression of cyclin B1 (P = .005) and (2) two or three alterations were significantly correlated with increased expression of cyclin A (P = .014). These findings suggest combined impairment of a complex cell-cycle control network involving the CDK inhibitor p27, the P53 pathway, and the Rbl pathway, which exerts a cooperative effect resulting in enhanced tumor cell proliferation